Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Imaging of IDH-mutant Gliomas
NCT03952598Phase 2Suspended
- Sponsor
- National Cancer Institute
- Start
- Oct 2019
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial (3 arms), sponsored by National Cancer Institute. Primary endpoint: Quantitative levels of 2-hydroxyglutarate (2-HG) at 5 years. Started Oct 2019; status: suspended.
Beyond the preview
Go deeper on NCT03952598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03952598.